+25.2%
VZ vs MRNA
+945.0%
-919.8%
-17.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.1% | +13.1% | -11.1% | +2.1% |
| 7D | +6.9% | +20.6% | -13.7% | +7.0% |
| 30D | +2.3% | +27.1% | -24.9% | +2.4% |
| 3M | 0.0% | +353.4% | -353.4% | +1.1% |
| 6M | +0.2% | +446.3% | -446.0% | +3.0% |
| YTD | +20.9% | +776.2% | -755.3% | +25.3% |
| 1Y | +25.2% | +987.9% | -962.7% | +25.9% |
| All | +25.2% | +945.0% | -919.8% | +25.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling